<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02193490</url>
  </required_header>
  <id_info>
    <org_study_id>UIC-CNBL-1001</org_study_id>
    <nct_id>NCT02193490</nct_id>
  </id_info>
  <brief_title>DNase Treatment for Dry Eyes</brief_title>
  <official_title>Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research to Prevent Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability and preliminary efficacy of DNase
      eye drops in patients with Sjogren's and Non-Sjogren Dry Eye Disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in ocular surface staining as measured by Rose Bengal dye staining</measure>
    <time_frame>Between baseline and at 8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in the Ocular Surface Disease Index score</measure>
    <time_frame>Between baseline and at 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ocular surface redness score on slit-lamp examination</measure>
    <time_frame>Between baseline and at 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in tear secretion as measured by Schirmer I test</measure>
    <time_frame>Between baseline and at 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of eyes achieving complete ocular surface staining clearance after treatment</measure>
    <time_frame>Between baseline and at 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity change</measure>
    <time_frame>Between baseline and at 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in number of corneal filaments (on slit-lamp examination)</measure>
    <time_frame>Between baseline and at 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in the test substance tolerance using visual analogue scale</measure>
    <time_frame>Between Day 1 (post-dose) and at weeks 2, 4, 6 and 8</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The proportion of subjects who were able to successfully complete a full eight weeks of therapy with topical administration four times per day</measure>
    <time_frame>Between baseline and at week 8</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>DNase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DNase 0.1% eye drops four times a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug vehicle eye drops four times a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNase</intervention_name>
    <description>DNase 0.1% eye drops four times a day for 8 weeks</description>
    <arm_group_label>DNase</arm_group_label>
    <other_name>Pulmozyme</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Drug vehicle eye drops four times a day for 8 weeks</description>
    <arm_group_label>Vehicle</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years or older.

          -  Capable of giving informed consent and does provide informed consent.

          -  Documented Dry Eye Disease for at least 6 months.

          -  Schirmer I &lt;10

          -  Corneal/ conjunctival (Rose Bengal) staining ≥1

          -  Ocular symptoms must be considered as annoying or activity limiting (OSDI ≥13; mild).

          -  Women must be post-menopausal ≥ 1 year, or surgically sterilized. If not, a negative
             urine pregnancy test is required within 14 days of receiving her first dose of test
             medication (placebo/ study drug) along with definite evidence of contraceptive use
             during the duration of the study.

        Exclusion Criteria:

          -  Allergic to Deoxyribonuclease eye drops or any similar products, or excipients of
             Deoxyribonuclease eye drops 0.1%.

          -  Receiving or have received within 30 days any experimental systemic medication.

          -  Active ocular infection or ocular allergies.

          -  Any history of eyelid surgery or ocular surgery within the past 3 months.

          -  Corneal epithelial defect larger than 1 mm2 in either eye.

          -  The use of topical cyclosporine or corticosteroids within 2 weeks of enrollment

          -  Have active drug/alcohol dependence or abuse history
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandeep Jain, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial, Line</last_name>
    <phone>312-918-0900</phone>
    <email>mun2@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandeep Jain, MD</last_name>
    <phone>312-996-8936</phone>
    <email>jains@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Translational Clinic of Corneal Neurobiology laboratory, Illinois Eye and Ear Infirmary, University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandeep Jain, MD</last_name>
      <phone>312-355-5220</phone>
      <email>jains@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Sandeep Jain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cornealneurobiology.uic.edu/</url>
    <description>Description of research laboratory</description>
  </link>
  <reference>
    <citation>Tibrewal S, Sarkar J, Jassim SH, Gandhi S, Sonawane S, Chaudhary S, Byun YS, Ivanir Y, Hallak J, Horner JH, Newcomb M, Jain S. Tear fluid extracellular DNA: diagnostic and therapeutic implications in dry eye disease. Invest Ophthalmol Vis Sci. 2013 Dec 11;54(13):8051-61. doi: 10.1167/iovs.13-12844.</citation>
    <PMID>24255046</PMID>
  </reference>
  <reference>
    <citation>Sonawane S, Khanolkar V, Namavari A, Chaudhary S, Gandhi S, Tibrewal S, Jassim SH, Shaheen B, Hallak J, Horner JH, Newcomb M, Sarkar J, Jain S. Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease. Invest Ophthalmol Vis Sci. 2012 Dec 17;53(13):8253-63. doi: 10.1167/iovs.12-10430.</citation>
    <PMID>23169882</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2014</study_first_posted>
  <last_update_submitted>January 11, 2018</last_update_submitted>
  <last_update_submitted_qc>January 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Sandeep Jain</investigator_full_name>
    <investigator_title>Associate Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>DNase, Pulmozyme, dry eye disease, treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

